Tag: Abbott And Galapagos enter into global collaboration to develop inhibitor fot anti-immune diseases
Abbott and Galapagos enter into global collaboration to develop inhibitor for anti-immune diseases
ABBOTT Laboratories recently announced that the company and Galapagos, a mid-size biotechnology company, have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases. […]
